Boundless Bio, Inc. (BOLD)
(Delayed Data from NSDQ)
$9.35 USD
+0.30 (3.31%)
Updated May 3, 2024 04:00 PM ET
After-Market: $9.27 -0.08 (-0.86%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth NA Momentum NA VGM
Boundless Bio, Inc. (BOLD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$22.50 | $25.00 | $20.00 | 148.62% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Boundless Bio, Inc. comes to $22.50. The forecasts range from a low of $20.00 to a high of $25.00. The average price target represents an increase of 148.62% from the last closing price of $9.05.
Analyst Price Targets (2 )
Broker Rating
Boundless Bio, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to no recommendation a month ago.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. There was no Strong Buy or Buy recommendation a month ago.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | NA | NA | NA | NA |
Buy | 0 | NA | NA | NA | NA |
Hold | 0 | NA | NA | NA | NA |
Sell | 0 | NA | NA | NA | NA |
Strong Sell | 0 | NA | NA | NA | NA |
ABR | 1.00 | NA | NA | NA | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/24/2024 | SVB Securities | Andrew Berens | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | NA |
# of Recs in ABR | 2 |
Average Target Price | $22.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -0.65 |